Giant Cell Arteritis (GCA) is an inflammatory symptom that affects blood vessels in middle-aged and elderly people.The disease involves large and mediumsized arteries in patients, especially the temporal arteries.The appearance of diseases affects the physical health of patients to a certain extent.Interleukin-6 plays an important role in a variety of immune responses and inflammatory responses.Tocilizumab is a kind of humanized monoclonal antibody that can bind and block the IL-6 receptor in a specific way, inhibit the IL-6 mediated signal transduction, alleviate inflammatory responses, and reduce inflammatory damage.This article is divided into four parts and describes the research progress of the immunomadological effects of anti-IL-6 receptor drug tocilizumab in giant cell arteritis.Firstly, the basic characteristics and mechanism of tocilizumab were analyzed, including chemical structure and biological activity, pharmacokinetic characteristics, and safety of tocilizumab.Secondly, the application of tocilizumab in the treatment of giant cell arteritis was discussed, including the efficacy analysis, dosage, and course of treatment.The challenges and limitations of tocilizumab in the treatment of giant cell arteritis were discussed again.Finally, the prospect of the proposition is summarized, hoping that this paper can provide reference materials for related personnel's research work.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: